Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey
American Journal of Preventive Cardiology · 2026-02 · 25 · 101388
DOI: 10.1016/j.ajpc.2025.101388 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-02. Verfasst von Nathan D Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation, University of California, Irvine.
Abstract (Originalsprache)
Background
Data are limited regarding national clinician awareness, testing, and treatment of lipoprotein(a) [Lp(a)]. We conducted a national survey of US clinicians to investigate these issues.
Methods
An internet-based survey of awareness, testing and treatment of Lp(a) was administered by a medical survey company to clinicians who have been in practice ≥5 years in the US or its territories.
Results
2002 clinicians completed the survey: 47 % were primary care, 35 % cardiology, 9 % endocrinology, and 9 % neurology. 28 % were female, 24 % Asian, 4 % Hispanic, and 3 % Black. Awareness: 81 % of respondents agreed Lp(a) is a significant risk driver for cardiovascular disease (CVD). 77 % and 75 % agreed knowing Lp(a) would help in risk stratification and increase patient engagement, respectively. Testing: 41 % of respondents agreed with universal testing of Lp(a). Most agreed Lp(a) should be measured in those with premature (73 %), family history of premature (71 %), or recurrent CVD events (68 %). Treatment: 77 % reported having CVD outcome data were felt to be very important for a new therapy, followed by long-term efficacy/safety data (69 %), real-world data (53 %), magnitude of Lp(a) reduction (21 %), dosing frequency (17 %), and mechanism of action (12 %). Clinicians reported being most likely to consider prescribing Lp(a)-targeted therapy with proven CVD benefit among patients with premature (47 %) or recurrent (51 %) CVD events.
Conclusion
Most clinicians agree knowing the Lp(a) level can improve risk assessment and patient engagement. Patients with premature or recurrent CVD events are most likely to be targeted for Lp(a) testing and for prescribing possible future Lp(a)-targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine.
- Novartis Pharmaceuticals Corporation.
Förderung
- Novartis Pharmaceuticals Corporation
- University of California, Irvine
Zitieren
APA
Wong, N. D., Fan, Y., Fan, W., Ward, J. H., Schludi, B., & Hu, X. (2026). Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey. American Journal of Preventive Cardiology, 25, 101388. https://doi.org/10.1016/j.ajpc.2025.101388
Vancouver
Wong ND, Fan Y, Fan W, Ward JH, Schludi B, Hu X. Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey. American Journal of Preventive Cardiology. 2026;25:101388. doi:10.1016/j.ajpc.2025.101388
BibTeX
@article{Wong2026,
author = {Wong, Nathan D and Fan, Yihang and Fan, Wenjun and Ward, Jonathan H and Schludi, Belinda and Hu, Xingdi},
title = {Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {25},
pages = {101388},
doi = {10.1016/j.ajpc.2025.101388}
}
EUVIMED